共 79 条
[1]
Xia C(2022)Cancer statistics in China and United States, 2022: profiles, trends, and determinants Chin Med J (Engl) 135 584-90
[2]
Dong X(2019)Molecular insight of regorafenib treatment for Colorectal cancer Cancer Treat Rev 81 101912-12
[3]
Li H(2013)Regorafenib monotherapy for previously treated metastatic Colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 303-29
[4]
Cao M(2015)Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic Colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 16 619-82
[5]
Sun D(2019)Regorafenib dose-optimisation in patients with refractory metastatic Colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study Lancet Oncol 20 1070-54
[6]
He S(2019)Safety and effectiveness of regorafenib in patients with metastatic Colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study Eur J Cancer 123 146-18
[7]
Arai H(2020)Pembrolizumab in microsatellite-instability-high Advanced Colorectal Cancer N Engl J Med 383 2207-61
[8]
Battaglin F(2020)Regorafenib Plus Nivolumab in patients with Advanced gastric or Colorectal Cancer: an Open-Label, Dose-Escalation, and dose-expansion phase ib trial (REGONIVO, EPOC1603) J Clin Oncol 38 2053-102
[9]
Wang J(2021)Regorafenib plus Toripalimab in patients with metastatic Colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis Cell Rep Med 2 100383-47
[10]
Lo JH(2022)A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory Colorectal cancer Eur J Cancer 169 93-4